EPA CAPSULES USED IN EMT2 RECEIVE A LICENCE FOR USE FOR PREVENTION OF HEART DISEASE IN THE UK
Update JULY 2021 The EPA capsules used in the EMT2 trial have now received approval from the MHRA (the drugs approvals agency in the UK) for use for prevention of cardiovascular (heart) disease in people with risk factors for heart disease (the medicine is called Vazkepa). As part of the...